about
A mitochondrial cytochrome b mutation causing severe respiratory chain enzyme deficiency in humans and yeastTrends in thyroid hormone prescribing and consumption in the UKGenetic basis and variable phenotypic expression of Kallmann syndrome: towards a unifying theory.Linkage Analysis in Autoimmune Addison's Disease: NFATC1 as a Potential Novel Susceptibility Locus.CTLA-4 as a genetic determinant in autoimmune Addison's disease.Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison's diseaseManagement of thyroid cancer: United Kingdom National Multidisciplinary GuidelinesSpontaneous and tetracosactide-induced anti-ACTH antibodies in man.A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans.Impact of Month of Birth on the Risk of Development of Autoimmune Addison's DiseaseHow should we treat patients with low serum thyrotropin concentrations?Autoimmune Addison disease: pathophysiology and genetic complexity.Diagnosis of Graves' orbitopathy (DiaGO): results of a pilot study to assess the utility of an office tool for practicing endocrinologists.High frequency of cytolytic 21-hydroxylase-specific CD8+ T cells in autoimmune Addison's disease patients.Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement.Correction: Linkage Analysis in Autoimmune Addison's Disease: NFATC1 as a Potential Novel Susceptibility Locus.Saving lives of in-patients with adrenal insufficiency: implementation of an alert scheme within the Newcastle-upon-Tyne Hospitals e-Prescribing platform.Residual adrenal function in autoimmune Addison's disease: improvement after tetracosactide (ACTH1-24) treatment.An elderly woman with weight loss and diarrhoea.Improving the prehospital safety of steroid-dependent patients in northern England: A hospital-initiated ambulance service registration pathway.Raising awareness of Graves' orbitopathy with early warning cards.The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy.Central lines and the general medical registrar - time for a change in the curriculum?Subclinical hyperthyroidism: first do no harmRole of the X-Linked GeneGPR174in Autoimmune Addison's DiseaseThe role of a nonsynonymous CD226 (DNAX-accessory molecule-1) variant (Gly 307Ser) in isolated Addison’s disease and autoimmune polyendocrinopathy type 2 pathogenesis
P50
Q28260897-46DCD9A2-6B11-4AFD-87B5-631A6A2B2C38Q33443457-21E04185-7F84-4FDF-A721-FB83CB9F5451Q34179909-A3583AF9-60B3-478B-8E9B-698806E57976Q35652433-2C8ABB6B-E9C5-47D3-9DAC-3DAF8520F5E7Q36032552-BD250CED-F2C5-4F5F-9C6C-0D058AB21511Q36293513-AE35C54A-55B4-4692-91A6-AE71D92B4955Q36919621-74247050-A8F5-4AC3-9877-AB5FEFD08AE0Q37105293-10B4F517-7C21-4EFB-A5D8-4C73DE866658Q37393239-04EF16CB-0F18-4F7B-B7BD-03155B020DC5Q37393271-47FCD4A6-EA69-481A-8264-FD424A89994EQ37594855-58672B53-952C-4E1A-8A74-8D28D557789AQ37980033-309BA35F-425B-4E25-8338-3B22248A96C4Q38285063-1EC1C852-E666-4078-B81B-D487AE42F6B6Q39882299-5B34CF18-630A-452B-9006-C33FB0A76D1BQ43165236-8C21821E-5627-46CB-85E9-C9F93F612656Q43246309-608507A0-1C8D-4A2A-9110-191920EB2CDBQ44821508-B8B224AD-34F2-49B9-ADD0-44DB8CFBCA0DQ45022944-643B5DFC-62FA-4536-B096-03B1F9DE2D75Q46003390-D2DD6AAE-E611-46F4-B182-5D67A584E0ACQ48187392-99FE2973-C7D4-4F4E-8308-EAD08D6957E4Q48325742-293068D1-68EF-4897-AD2B-312117D96B3AQ50795971-CCB91F38-6DF0-4621-98BB-9494954D21C7Q51023782-11C9B5C3-AF3C-401D-ACDD-E14B96E96F70Q62132440-D2CDF733-243E-4918-A114-2A00DAC082B6Q62132458-381D2B2B-2C94-42B4-9A31-25828B000F58Q62132469-B8123A66-4808-44A4-B25B-984BBD4D5ED6
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anna L Mitchell
@ast
Anna L Mitchell
@en
Anna L Mitchell
@es
Anna L Mitchell
@nl
type
label
Anna L Mitchell
@ast
Anna L Mitchell
@en
Anna L Mitchell
@es
Anna L Mitchell
@nl
prefLabel
Anna L Mitchell
@ast
Anna L Mitchell
@en
Anna L Mitchell
@es
Anna L Mitchell
@nl
P106
P21
P31
P496
0000-0002-9946-183X